Neurocrine Biosciences vs Revvity

Neurocrine Biosciences (NBIX), health care, and Revvity (RVTY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Neurocrine Biosciences and Revvity are valued at about the same: $16.8B and $16.5B. Neurocrine Biosciences trades at 24.5 times earnings and Revvity at 66.3; operating margins in their latest fiscal years were 21.6% and 12.5%. Over the past year Neurocrine Biosciences's share price has moved +19.2% and Revvity's +60.0%.

Key facts

Neurocrine Biosciences market value
$16.8B
Revvity market value
$16.5B
Neurocrine Biosciences P/E
24.5
Revvity P/E
66.3
Neurocrine Biosciences revenue
$2.9BFY to 2025-12-31
Revvity revenue
$2.9BFY to 2025-12-28
Superinvestors holding both
0

Market values as of .

Neurocrine Biosciences vs Revvity: every measure side by side
Measure Neurocrine Biosciences Revvity
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-28
Size
Market cap$16.8Bhigher$16.5Blower
Revenue$2.9Bhigher$2.9Blower
Earnings$478.6Mhigher$241.2Mlower
Employees2,500lower11,000higher
Total assets$4.6Blower$12.2Bhigher
Valuation
P/E24.5lower66.3higher
P/S5.9higher5.8lower
P/B4.3higher2.3lower
Dividend yield0.00%lower0.19%higher
Profitability
Operating margin21.6%higher12.5%lower
Balance sheet
Net assets$3.3Blower$7.3Bhigher
Total liabilities$1.4Blower$4.9Bhigher
Total debt—$3.2B
Cash on hand$713Mlower$919.9Mhigher
Price change
Today+0.37%higher-0.71%lower
1 year+19.2%lower+60.0%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Revvity only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns NBIX · Who owns RVTY

Further comparisons

Learn

Questions and answers

Which is bigger, Neurocrine Biosciences or Revvity?

By market value, Neurocrine Biosciences is the larger: $16.8B against $16.5B for Revvity. By revenue in its latest fiscal year, Neurocrine Biosciences is the larger: $2.9B against $2.9B for Revvity.

Which has the higher P/E ratio?

Revvity: 66.3, against 24.5 for Neurocrine Biosciences. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Neurocrine Biosciences: 21.6%, against 12.5% for Revvity. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Revvity: 0.19%, against 0.00% for Neurocrine Biosciences. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Neurocrine Biosciences and Revvity?

None of the tracked superinvestors holds both in their latest 13F filing. 5 hold Neurocrine Biosciences and 3 hold Revvity.

Cite this page

Funkfolio, “Neurocrine Biosciences vs Revvity”, data as of 18 November 2026. https://funkfolio.com/compare/nbix-vs-rvty

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.